Design of second generation HIV-1 integrase inhibitors

Current Pharmaceutical Design

Volumn 13, Issue 2, 2007, Pages 129-141

  Deng, Jinxia ^a   Dayam, Raveendra ^a   Al Mawsawi, Laith Q ^a   Neamati, Nouri ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

810; Antiretroviral drugs; Database screening; HIV 1 integrase inhibitor; L 870; Pharmacophore; S 1360

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; 4 HYDROXYCOUMARIN; AMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; CAFFEIC ACID PHENETHYL ESTER; CICHORIC ACID; INTEGRASE; INTEGRASE INHIBITOR; L 708906; L 870812; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; NAPHTHYRIDINE DERIVATIVE; NSC 115290; NSC 117027; NSC 158393; PURPURIN; QUERCETIN; QUINALIZARIN; TETRACYCLINE; UNCLASSIFIED DRUG; V 165;

ABSENCE OF SIDE EFFECTS; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG POTENCY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PHARMACOPHORE; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE;

ANIMALS; DRUG DESIGN; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS;

EID: 33846164748     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207779313687     Document Type: Review

References (60)

1. Schiller DS. Identification, management, and prevention of adverse effects associated with highly active antiretroviral therapy. Am J Health Syst Pharm 2004; 61: 2507-22.
2. Hertogs K, Bloor S, Kemp SD, Van den Eynde C, Alcorn TM, Pauwels R, et al. Phenotypic and genotypic analysis of clinical HIV-1 isolates reveals extensive protease inhibitor cross-resistance: a survey of over 6000 samples. AIDS 2000; 14: 1203-10.
3. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995; 374: 569-71.
4. Roberts NA, Craig JC, Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS 1998; 12: 453-60.
5. Shirasaka T, Kavlick MF, Ueno T, Gao WY, Kojima E, Alcaide ML, et al. Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995; 92: 2398-402.
6. Iversen AK, Shafer RW, Wehrly K, Winters MA, Mullins JI, Chesebro B, et al. Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. J Virol 1996; 70: 1086-90.
7. Baldanti F, Paolucci S, Maga G, Labo N, Hubscher U, Skoblov AY, et al. Nevirapine-selected mutations Y181I/C of HIV-1 reverse transcriptase confer cross-resistance to stavudine. AIDS 2003; 17: 1568-70.
8. Blower SM, Aschenbach AN, Gershengorn HB, Kahn JO. Predicting the unpredictable: transmission of drug-resistant HIV. Nat Med 2001; 7: 1016-20.
9. Hecht FM, Grant RM, Petropoulos CJ, Dillon B, Chesney MA, Tian H, et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998; 339: 307-11.
10. Brown PO. In: Coffin JM, Hughes SH, Varmus HE, ed., Retroviruses, New York, Cold Spring Harbor Laboratory Press. 1997; pp. 161-203.
11. Asante-Appiah E, Skalka AM. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv Virus Res 1999; 52: 351-69.
12. Schroder AR, Shinn P, Chen H, Berry C, Ecker JR, Bushman F. HIV-1 integration in the human genome favors active genes and local hotspots. Cell 2002; 110: 521-9.
13. LaFemina RL, Schneider CL, Robbins HL, Callahan PL, LeGrow K, Roth E, et al. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells. J Virol 1992; 66: 7414-9.
14. Neamati N. Patented small molecule inhibitors of HIV-1 integrase: a 10-year saga. Expert Opin Ther Pat 2002; 12: 709-24.
15. Neamati N. Structure-based HIV-1 integrase inhibitor design: a future perspective. Expert Opin Investig Drugs 2001; 10: 281-96.
16. Dayam R, Neamati N. Small-molecule HIV-1 integrase inhibitors: the 2001-2002 update. Curr Pharm Des 2003; 9: 1789-802.
17. Johnson AA, Marchand C, Pommier Y. HIV-1 integrase inhibitors: a decade of research and two drugs in clinical trial. Curr Top Med Chem 2004; 4: 1059-77.
18. De Clercq E. New approaches toward anti-HIV chemotherapy. J Med Chem 2005; 48: 1297-313.
19. Pommier Y, Johnson AA, Marchand C. Integrase inhibitors to treat HIV/ AIDS. Nat Rev Drug Discov 2005; 4: 236-48.
20. Mekouar K, Mouscadet JF, Desmaele D, Subra F, Leh H, Savoure D, et al. Styrylquinoline derivatives: a new class of potent HIV-1 integrase inhibitors that block HIV-1 replication in CEM cells. J Med Chem 1998; 41: 2846-57.
21. Pannecouque C, Pluymers W, Van Maele B, Tetz V, Cherepanov P, De Clercq E, et al. New class of HIV integrase inhibitors that block viral replication in cell culture. Curr Biol 2002; 12: 1169-77.
22. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287: 646-50.
23. Hazuda DJ, Anthony NJ, Gomez RP, Jolly SM, Wai JS, Zhuang L, et al. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci USA 2004; 101: 11233-8.
24. Yoshinaga TS A, Fujishita T, Fujiwara T. In 9th Conference on retroviruses and opportunistic infections: Seattle, WA, 2002.
25. Young S. In XIV international AIDS conference: West Point, PA, USA, 2002.
26. Billich A. S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs 2003; 4: 206-9.
27. Fikkert V, Hombrouck A, Van Remoortel B, De Maeyer M, Pannecouque C, De Clercq E, et al. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 2004; 18: 2019-28.
28. Rosemond MJ, St John-Williams L, Yamaguchi T, Fujishita T, Walsh JS. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact 2004; 147: 129-39.
29. Fikkert V, Van Maele B, Vercammen J, Hantson A, Van Remoortel B, Michiels M, et al. Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations. J Virol 2003; 77: 11459-70.
30. Hazuda DJ, Young SD, Guare JP, Anthony NJ, Gomez RP, Wai JS, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004; 305: 528-32.
31. Maurin C, Bailly F, Buisine E, Vezin H, Mbemba G, Mouscadet JF, et al. Spectroscopic studies of diketoacids-metal interactions. A probing tool for the pharmacophoric intermetallic distance in the HIV-1 integrase active site. J Med Chem 2004; 47: 5583-6.
32. Guner OF. Pharmacophore perception, development, and use in drug design, La Jolla, IUL Biotechnology Series: 2000.
33. Milne GW, Nicklaus MC, Wang S. Pharmacophores in drug design and discovery. SAR QSAR Environ Res 1998; 9: 23-38.
34. Fang X, Wang S. A web-based 3D-database pharmacophore searching tool for drug discovery. J Chem Inf Comput Sci 2002; 42: 192-8.
35. Clement OO, Freeman CM, Hartmann RW, Handratta VD, Vasaitis TS, Brodie AM, et al. Three dimensional pharmacophore modeling of human CYP17 inhibitors. Potential agents for prostate cancer therapy. J Med Chem 2003; 46: 2345-51.
36. Guner O, Clement O, Kurogi Y. Pharmacophore modeling and three dimensional database searching for drug design using catalyst: recent advances. Curr Med Chem 2004; 11: 2991-3005.
37. Fesen MR, Pommier Y, Leteurtre F, Hiroguchi S, Yung J, Kohn KW. Inhibition of HIV-1 integrase by flavones, caffeic acid phenethyl ester (CAPE) and related compounds. Biochem Pharmacol 1994; 48: 595-608.
38. Mazumder A, Wang S, Neamati N, Nicklaus M, Sunder S, Chen J, et al. Antiretroviral agents as inhibitors of both human immunodeficiency vinis type 1 integrase and protease. J Med Chem 1996; 39: 2472-81.
39. Hong H, Neamati N, Wang S, Nicklaus MC, Mazumder A, Zhao H, et al. Discovery of HIV-1 integrase inhibitors by pharmacophore searching. J Med Chem 1997; 40: 930-6.
40. Neamati N, Hong H, Mazumder A, Wang S, Sunder S, Nicklaus MC, et al. Depsides and depsidones as inhibitors of HIV-1 integrase: discovery ofnovel inhibitors through 3D database searching. J Med Chem 1997; 40: 942-51.
41. Nicklaus MC, Neamati N, Hong H, Mazumder A, Sunder S, Chen J, et al. HIV-1 integrase pharmacophore: discovery of inhibitors through three-dimensional database searching. J Med Chem 1997; 40: 920-9.
42. Neamati N, Hong H, Sunder S, Milne GW, Pommier Y. Potent inhibitors of human immunodeficiency virus type 1 integrase: identification of a novel four-point pharmacophore and tetracyclines as novel inhibitors. Mol Pharmacol 1997; 52: 1041-55.
43. Yuan H, Parrill AL. QSAR studies of HIV-1 integrase inhibition. Bioorg Med Chem 2002; 10: 4169-83.
44. Hong H, Neamati N, Winslow HE, Christensen JL, Orr A, Pommier Y, et al. Identification of HIV-1 integrase inhibitors based on a four-point pharmacophore. Antivir Chem Chemother 1998; 9: 461-72.
45. Accelrys, INC.: San Diego.
46. Barreca ML, Rao A, De Luca L, Zappala M, Gurnari C, Monforte P, et al. Efficient 3D database screening for novel HIV-1 IN inhibitors. J Chem Inf Comput Sci 2004; 44: 1450-5.
47. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, et al. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design. Proc Natl Acad Sci USA 1999; 96: 13040-3.
48. Mustata GI, Brigo A, Briggs JM. HIV-1 integrase pharmacophore model derived from diverse classes of inhibitors. Bioorg Med Chem Lett 2004; 14: 1447-54.
49. Dayam R, Sanchez T, Clement O, Shoemaker R, Sei S, Neamati N. Beta-diketo acid pharmacophore hypothesis. 1. Discovery of a novel class of HIV-1 integrase inhibitors. J Med Chem 2005; 48: 111-20.
50. Smellie A, Dyda F, Hickman AB. Poling-Promoting conformational variation. J Comput Chem 1995; 16: 171-87.
51. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 2001; 46: 3-26.
52. Carlson HA, Masukawa KM, Rubins F, Bushman FD, Jorgensen WL, Lins RD, et al. Developing a dynamic pharmacophore model for HIV-1 integrase. J Med Chem 2000; 43: 2100-14.
53. Dyda F, Hickman AB, Jenkins TM, Engelman A, Craigie R, Davies DR. Crystal structure of the catalytic domain of HIV-1 integrase: similarity to other polynucleotidyl transferases. Science 1994; 266: 1981-6.
54. Bujacz G, Jaskolski M, Alexandratos J, Wlodawer A, Merkel G, Katz RA, et al. High-resolution structure of the catalytic domain of avian sarcoma virus integrase. J Mol Biol 1995; 253: 333-46.
55. Deng J, Lee KW, Sanchez T, Cui M, Neamati N, Briggs JM. Dynamic receptor-based pharmacophore model development and its application in designing novel HIV-1 integrase inhibitors. J Med Chem 2005; 48: 1496-505.
56. Lee MC, Deng J, Briggs JM, Duan Y. Large-scale conformational dynamics of the HIV-1 integrase core domain and its catalytic loop mutants. Biophys J 2005; 88: 3133-46.
57. Wang RX, Gao Y, Lai LH. LigBuilder: A multi-purpose program for structure-based drug design. J Mol Model 2000; 6: 498-516.
58. Abrescia N, D'Abbraccio M, Figoni M, Busto A, Maddaloni A, De Marco M. Hepatotoxicity of antiretroviral drugs. Curr Pharm Des 2005; 11(28): 3697-710.
59. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state ofthe art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005; 11(14): 1805-43.
60. Debnath AK. Application of 3D-QSAR techniques in anti-HIV-1 drug design - an overview. Curr Pharm Des 2005; 11(24): 3091-110.